hiberix powder & diluent for sol for inj; haemophilus influenzae type b (hib) conjugated vaccine
glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - haemophilus influenzae, b, tetanus toxoid - powder and solvent for solution for infusion - haemophilus influenzae b 10 µg tetanus toxoid 25 µg - vaccines
bacitracin zinc and polymyxin b sulfate ointment
nucare pharmaceuticals,inc. - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.
zepzelca- lurbinectedin injection, powder, lyophilized, for solution
jazz pharmaceuticals, inc. - lurbinectedin (unii: 2cn60tn6zs) (lurbinectedin - unii:2cn60tn6zs) - zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy. this indication is approved under accelerated approval based on overall response rate and duration of response [see clinical studies (14) ] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). none. risk summary based on animal data and its mechanism of action [see clinical pharmacology (12.1)] , zepzelca can cause fetal harm when administered to a pregnant woman. there are no available data to inform the risk of zepzelca use in pregnant women. intravenous administration of a single lurbinectedin dose (approximately 0.2 times the 3.2 mg/m2 clinical dose) to pregnant rats during the period of organogenesis caused embryolethality (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and mi
bacitracin zinc and polymyxin b sulfate ointment
rpk pharmaceuticals, inc. - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin b sulfate. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.
cixtor-z syrup
solvang pharmaceuticals, inc. - ascorbic acid , zinc - syrup - 100 mg/10 mg (equivalent to 27.45mg zinc sulfate monohydrate ) per 5ml syrup
enhancee capsule
aldril pharmaceutical inc. - ascorbic acid , zinc - capsule - 500 mg (equivalent to 532.43 mg sodium ascorbate /10 mg (equivalent to 70 mg zinc gluconate) capsule
ascorb z+ capsule
westfield pharmaceuticals, inc. - ascorbic acid , zinc - capsule - 500 mg (equivalent to 562.43 mg sodium ascorbate)/ 10 mg (equivalent to 70 mg zinc gluconate)
immutrax capsule
metz pharmaceuticals, inc.; importer: n/a; distributor: n/a - ascorbic acid , zinc - capsule - 500 mg (equivalent to 568.18 mg sodium ascorbate) / 10 mg (equivalent to 27.5 mg zinc sulfate monohydrate)
healthy c-plus capsule
interhealthcare pharmaceuticals inc.; importer: n/a; distributor: n/a - ascorbic acid , zinc - capsule - 500 mg (equivalent to 568.18 mg sodium ascorbate) / 10 mg (equivalent to 27.5 mg zinc sulfate monohydrate)
ascor-z plus capsule
n/a; distributor: red drug pharmaceutical inc. - ascorbic acid , zinc - capsule - 500 mg (equivalent to 562.5 mg sodium ascorbate) / 10 mg (equivalent to 27.5 mg zinc sulfate monohydrate)